Co-mutation in KRAS and Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor erythroid 2-related factor 2 (NFE2L2) in NSCLC is an independent prognostic factor, predicting shorter survival, duration of response to initial platinum-based chemotherapy, and survival from the start of immune therapy [25]. Here, KRAS is linked to non-small cell lung carcinoma.